The FDA granted traditional approval to pirtobrutinib (Jaypirca) for relapsed/refractory chronic lymphocytic leukemia/small ...

Squamous cell carcinoma treatment varies by stage, involving surgery, radiation, and systemic therapies based on cancer ...

Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options, highlighting the latest advancements in ...

The increasing incidence of early-onset lung cancer has become a focal point of research, as it challenges the traditional association of lung cancer with older age. Despite a general decline in ...

Incidence of Venous Thromboembolic Events in Patients with Metastatic Pancreatic Adenocarcinoma Receiving Palliative ...

Elevar plans resubmission of a New Drug Application to the U.S. Food and Drug Administration for the combination therapy of camrelizumab and rivoceranib in January 2026.

The companies plan to test the treatment's efficacy in preclinical models of squamous cell lung carcinoma early next year.

A new program launched by UR Medicine primary care in 2022 has helped more than double lung screening rates. A recent study ...

Senescent fibroblasts are aging cells that no longer divide and protect against tumor development. Yet two decades have gone ...

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...

Current U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelines miss about two-thirds of patients with ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...